The biosimilar slugfest
In this issue:
How Big Pharma is coping with the biosimilar threat
In just a few short years, many Big Pharma biologics manufacturers will be seriously out of pocket when their blockbuster compounds go off patent. Or will they? Although slow to react, many pharmaceuticals heavyweights have moved into the offensive to stave off huge potential losses. Now they are setting up biosimilar arms of their own, while many are reinventing their antibodies to perform as highly-specific delivery systems for tumour-killing therapeutics. Can ADCs take mABs to the next level?